Sisram Medical Ltd. (HK:1696)
:1696
Want to see HK:1696 full AI Analyst Report?
Top Page
Sisram Medical Ltd.
(1696)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$4.50
▲(16.28% Upside)
Action:ReiteratedDate:12/20/25
The overall score of 62 for Sisram Medical Ltd. is primarily driven by mixed financial performance, with strengths in low leverage offset by a concerning 46.8% revenue decline. Valuation remains reasonable with a P/E of 12.76 and a 2.88% dividend yield, while technical indicators suggest neutral momentum. Financial performance carries the most weight in this assessment.
Positive Factors
Profitability Margins
High profitability margins indicate effective cost management and pricing power, supporting long-term financial health and competitive positioning.
Negative Factors
Revenue Growth Decline
A significant decline in revenue growth can impact market share and long-term viability, necessitating strategic adjustments to regain growth momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Margins
High profitability margins indicate effective cost management and pricing power, supporting long-term financial health and competitive positioning.
Read all positive factors
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.47B
Dividend Yield2.82%
Average Volume (3M)469.37K
Price to Earnings (P/E)13.3
Beta (1Y)1.20
Revenue Growth4.57%
EPS Growth-24.35%
CountryHK
Employees1,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.21
Shares Outstanding468,343,080
10 Day Avg. Volume515,040
30 Day Avg. Volume469,367
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)0.49
Price to Sales (P/S)0.65
P/FCF Ratio7.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.50Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.39
Revenue Forecast (FY)HK$3.22B
Sisram Medical Ltd. Business Overview & Revenue Model
Company Description
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North ...
How the Company Makes Money
Sisram Medical generates revenue through the sale of its advanced medical devices and equipment to healthcare professionals, clinics, and aesthetic practices. The primary source of income stems from direct sales of its laser systems and technologi...
Sisram Medical Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 345.86M | 349.11M | 359.29M | 354.48M | 294.29M | 162.09M |
| Gross Profit | 210.72M | 216.68M | 219.53M | 202.23M | 166.86M | 90.30M |
| EBITDA | 33.03M | 38.91M | 53.43M | 58.38M | 55.96M | 28.19M |
| Net Income | 20.60M | 25.13M | 31.50M | 40.17M | 31.25M | 13.34M |
Balance Sheet | ||||||
| Total Assets | 633.26M | 627.26M | 613.50M | 555.60M | 530.13M | 431.81M |
| Cash, Cash Equivalents and Short-Term Investments | 62.01M | 71.98M | 70.60M | 91.49M | 157.96M | 116.37M |
| Total Debt | 46.97M | 43.20M | 44.68M | 41.34M | 41.62M | 37.06M |
| Total Liabilities | 145.56M | 142.47M | 143.98M | 123.38M | 126.51M | 99.92M |
| Stockholders Equity | 466.38M | 464.03M | 452.31M | 430.87M | 402.18M | 331.89M |
Cash Flow | ||||||
| Free Cash Flow | 20.87M | 30.38M | 35.37M | -42.28M | 29.41M | 16.46M |
| Operating Cash Flow | 24.23M | 33.08M | 43.94M | 22.04M | 32.38M | 25.74M |
| Investing Cash Flow | -17.64M | -6.59M | -32.99M | -52.11M | -46.77M | -33.51M |
| Financing Cash Flow | -18.79M | -16.11M | -20.97M | -17.85M | 55.78M | -12.21M |
Sisram Medical Ltd. Technical Analysis
Negative
3.87
Price Trends
3.69
Negative
3.99
Negative
4.63
Negative
Market Momentum
-0.16
Positive
38.96
Neutral
18.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 3.87 is above the 20-day moving average (MA) of 3.36, above the 50-day MA of 3.69, and below the 200-day MA of 4.63, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 38.96 is Neutral, neither overbought nor oversold. The STOCH value of 18.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.
Sisram Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.67B | 17.31 | 11.91% | 1.26% | 10.19% | 23.37% | |
68 Neutral | HK$9.16B | 42.52 | 4.02% | ― | 5.10% | -32.48% | |
62 Neutral | HK$1.47B | 13.30 | 4.02% | 2.82% | 4.57% | -24.35% | |
59 Neutral | HK$3.19B | 31.51 | 7.22% | ― | 20.65% | 127.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$4.43B | -18.13 | -11.27% | ― | 16.35% | 9.43% | |
44 Neutral | HK$3.28B | 17.15 | 2.04% | ― | 90.81% | ― |
* Healthcare Sector Average
HK:1696
Sisram Medical Ltd.
3.02
-1.19
-28.27%
HK:9996
Peijia Medical Ltd.
6.38
1.07
20.15%
HK:6669
Acotec Scientific Holdings Limited
10.49
2.41
29.83%
HK:1302
LifeTech Scientific Corporation
2.08
0.64
44.44%
HK:1789
AK Medical Holdings Ltd.
6.71
1.12
20.04%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.98
1.75
28.09%
Sisram Medical Ltd. Corporate Events
Sisram Medical Clears Key Regulatory Hurdle for DAXXIFY Injection in Mainland China
Jan 5, 2026
Sisram Medical has announced that its sublicensed botulinum toxin type A injectable, DAXXIFY (DaxibotulinumtoxinA-lanm), for treating moderate to severe glabellar lines in adults, has passed quality testing by China’s National Institutes for...
Sisram Medical Announces Leadership Restructuring for 2026
Dec 8, 2025
Sisram Medical Ltd has announced significant changes in its leadership structure, effective from January 1, 2026. Mr. Yi Liu will transition from Chairman to a non-executive Director, while Mr. Lior Moshe Dayan will become the new Chairman. Mr. Ey...
Sisram Medical Ltd Announces New Board of Directors for 2026
Dec 8, 2025
Sisram Medical Ltd has announced the composition of its board of directors effective from January 1, 2026. The board includes a mix of executive, non-executive, and independent non-executive directors, with Mr. Lior Moshe Dayan serving as Chairman...
Sisram Medical Reports Strong Q3 Growth and Strategic Expansion Plans
Oct 28, 2025
Sisram Medical Ltd announced strong market momentum in Q3 2025, driven by increased demand in China, South Korea, and Thailand. The company reported a healthy double-digit year-on-year growth in unaudited revenue, with significant orders for its A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.